The pulmonary emphysema market is poised for steady growth driven by rising COPD prevalence, an aging global population, and greater diagnostic awareness. Advances in inhaled therapies, targeted ...

Chronic obstructive pulmonary disease is a condition caused by damage to the lungs that results in breathing difficulties.

Regardless of blood eosinophil count threshold, adults with COPD and an eosinophilic phenotype experienced significantly fewer moderate/severe exacerbations in a year with mepolizumab vs. placebo, ...

COPD research needs to increase focus on rural health disparities and consider the impact of sociocultural and environmental ...

Please provide your email address to receive an email when new articles are posted on . “We found a stepwise greater loss of lung density with increasing exacerbation frequency, predominantly in ...

COPD is a group of lung diseases that get worse over time. It prevents airflow to the lungs, causing breathing problems and ...

In Tarrant County, patients with severe chronic obstructive pulmonary disease, COPD, now have access to a procedure that can lessen airflow blockage and improve their quality of life. KERA’s Sam Baker ...

More than 11 million people in the United States are living with chronic obstructive pulmonary disease (COPD), including more than 3 million people with emphysema, a type of COPD. This chronic lung ...

The emphysema market is anticipated to grow steadily, fueled by a range of emerging therapies under development. Leading candidates like SAR447537 (Sanofi), Alvelestat (Mereo BioPharma), BEAM-302 ...

One patient could only walk 15 to 20 steps before needing to get back on her oxygen, making it difficult to find motivation to engage in daily activities. Another patient struggled with severe ...

Objectives There is a lack of knowledge about whether occupational exposures increase the risk of emphysema, especially in ...